Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead

Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li

doi:10.1016/j.addr.2014.11.004

Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead

Tony Velkov
, Nusaibah Abdul Rahim
, Qi Tony Zhou
, Hak-Kim Chan
, Jian Li

Drug Delivery Disposition & Dynamics

Research output: Contribution to journal › Article › Research › peer-review

85 Citations (Scopus)

Abstract

One of the most common causes of illnesses in humans is from respiratory tract infections caused by bacterial, viral or fungal pathogens. Inhaled anti-infective drugs are crucial for the prophylaxis and treatment of respiratory tract infections. The benefit of anti-infective drug delivery via inhalation is that it affords delivery of sufficient therapeutic dosages directly to the primary site of infection, while minimizing the risks of systemic toxicity or avoiding potential suboptimal pharmacokinetics/pharmacodynamics associated with systemic drug exposure. This review provides an up-to-date treatise of approved and novel developmental inhaled anti-infective agents, with particular attention to effective strategies for their use, pulmonary pharmacokinetic properties and safety.

Original language	English
Pages (from-to)	65 - 82
Number of pages	18
Journal	Advanced Drug Delivery Reviews
Volume	85
DOIs	https://doi.org/10.1016/j.addr.2014.11.004
Publication status	Published - 2015

Access to Document

10.1016/j.addr.2014.11.004

Cite this

@article{eec8010085ac4c299584d1c8b583df71,

title = "Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead",

abstract = "One of the most common causes of illnesses in humans is from respiratory tract infections caused by bacterial, viral or fungal pathogens. Inhaled anti-infective drugs are crucial for the prophylaxis and treatment of respiratory tract infections. The benefit of anti-infective drug delivery via inhalation is that it affords delivery of sufficient therapeutic dosages directly to the primary site of infection, while minimizing the risks of systemic toxicity or avoiding potential suboptimal pharmacokinetics/pharmacodynamics associated with systemic drug exposure. This review provides an up-to-date treatise of approved and novel developmental inhaled anti-infective agents, with particular attention to effective strategies for their use, pulmonary pharmacokinetic properties and safety.",

author = "Tony Velkov and \{Abdul Rahim\}, Nusaibah and Zhou, \{Qi Tony\} and Hak-Kim Chan and Jian Li",

year = "2015",

doi = "10.1016/j.addr.2014.11.004",

language = "English",

volume = "85",

pages = "65 -- 82",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead

AU - Velkov, Tony

AU - Abdul Rahim, Nusaibah

AU - Zhou, Qi Tony

AU - Chan, Hak-Kim

AU - Li, Jian

PY - 2015

Y1 - 2015

N2 - One of the most common causes of illnesses in humans is from respiratory tract infections caused by bacterial, viral or fungal pathogens. Inhaled anti-infective drugs are crucial for the prophylaxis and treatment of respiratory tract infections. The benefit of anti-infective drug delivery via inhalation is that it affords delivery of sufficient therapeutic dosages directly to the primary site of infection, while minimizing the risks of systemic toxicity or avoiding potential suboptimal pharmacokinetics/pharmacodynamics associated with systemic drug exposure. This review provides an up-to-date treatise of approved and novel developmental inhaled anti-infective agents, with particular attention to effective strategies for their use, pulmonary pharmacokinetic properties and safety.

AB - One of the most common causes of illnesses in humans is from respiratory tract infections caused by bacterial, viral or fungal pathogens. Inhaled anti-infective drugs are crucial for the prophylaxis and treatment of respiratory tract infections. The benefit of anti-infective drug delivery via inhalation is that it affords delivery of sufficient therapeutic dosages directly to the primary site of infection, while minimizing the risks of systemic toxicity or avoiding potential suboptimal pharmacokinetics/pharmacodynamics associated with systemic drug exposure. This review provides an up-to-date treatise of approved and novel developmental inhaled anti-infective agents, with particular attention to effective strategies for their use, pulmonary pharmacokinetic properties and safety.

UR - http://www.sciencedirect.com/science/article/pii/S0169409X14002671/pdfft?md5=7e74d784f4893bf67c4b448143b40604&pid=1-s2.0-S0169409X14002671-main.pdf

U2 - 10.1016/j.addr.2014.11.004

DO - 10.1016/j.addr.2014.11.004

M3 - Article

C2 - 25446140

SN - 0169-409X

VL - 85

SP - 65

EP - 82

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

ER -

Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead

Abstract

Access to Document

Other files and links

New tricks for 'old' drugs:PK/PD of polymyxin nonantibiotic combinations

Novel inhalation formulation of colistin and combination therapy against Gram-negative 'superbugs'.

Targeting Superbugs: discovery and development of new broad-spectrum lipopeptide

Cite this

Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead

Abstract

Access to Document

Other files and links

Projects

New tricks for 'old' drugs:PK/PD of polymyxin nonantibiotic combinations

Novel inhalation formulation of colistin and combination therapy against Gram-negative 'superbugs'.

Targeting Superbugs: discovery and development of new broad-spectrum lipopeptide

Cite this